# Role of hypoxia in CD8+ T cell exclusion and suppression in pancreatic cancer

> **NIH NIH F31** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $41,664

## Abstract

PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy characterized by poor response to all existing
therapies. Although immunotherapy has shown great promise against multiple deadly cancers, single-agent
checkpoint immunotherapy has been largely ineffective in PDAC. This lack of response is in part attributed to its
extensive inflammatory, desmoplastic stromal reaction and hypoxic microenvironment. Although tumor hypoxia
induces adaptive changes in both cancer cells and the surrounding stroma, most studies on the role of hypoxia
in tumorigenesis have focused on cancer cell-intrinsic properties. The impact of hypoxia on stromal cells
themselves and their interactions with cancer cells has remained largely unknown. The major cell populations
found within the PDAC stroma—macrophages and fibroblasts—are known to be large producers of
immunosuppressive factors, some of which can negatively affect cytotoxic CD8+ T cell activity in tumors. CD8+
T cells play an essential role in the anti-tumor response and the efficacy of immunnotherapies relies on the
amount of CD8+ T cell infiltration within the tumor bed. Based on our preliminary observation that macrophages
and inflammatory fibroblasts are enriched in hypoxic tumor regions while T cells are excluded from hypoxic areas
in PDAC, I hypothesize that hypoxia suppresses infiltration and activation of CD8+ T cells by modulating their
interactions with macrophages and fibroblasts. In Specific Aim 1, I will determine whether macrophages are
critical for hypoxia-mediated CD8+ T cell exclusion and suppression by treating CD8+ T cells with conditioned
media derived from macrophage cultures under hypoxia and depleting macrophages in syngeneic orthotopic
PDAC tumors. In Specific Aim 2, I will determine how fibroblasts regulate CD8+ T cell recruitment and function
in hypoxic tumor regions by blocking a factor secreted from fibroblasts in syngeneic orthotopic PDAC tumors,
injecting a hypoxia probe into mice, and assessing CD8+ T cell infiltration and activation in hypoxic and normoxic
tumor regions. The results of my studies will further the field’s understanding of how hypoxia drives an
immunosuppressive microenvironment via the crosstalk between CD8+ T cells, macrophages, and fibroblasts,
and thus aid in the development of effective immunotherapeutic strategies.

## Key facts

- **NIH application ID:** 10886509
- **Project number:** 5F31CA281079-02
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Ashley Mello
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $41,664
- **Award type:** 5
- **Project period:** 2023-09-01 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10886509

## Citation

> US National Institutes of Health, RePORTER application 10886509, Role of hypoxia in CD8+ T cell exclusion and suppression in pancreatic cancer (5F31CA281079-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10886509. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*